spacer
home > ict > winter 2020 > keeping trials connected
PUBLICATIONS
International Clinical Trials

Keeping Trials Connected




Staying up to date with the latest advances in cellular technologies is exhausting at best. Sometimes, just keeping the acronyms straight can be too much to handle (see NBIoT, Cat-M1, and EC-GSM-IoT), let alone adding in the complications that come with supporting an international clinical trial deployment. If you haven’t yet experienced these dynamics, just sit down with someone in your technical operations group and ask why device certification and cellular band support matter when it comes to clinical trials in Japan.

While it’s true that connected clinical trials have moved from being a value differentiator to simply becoming an industry standard, it is estimated that most people live more than two hours away from a clinical study site. Connectivity dramatically shortens that distance, virtually. The ability to retain clinical trial participants increases dramatically with less reliance upon the study site.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Stephen Byrne currently serves as the EU Managing Director of KORE. With more than 20 years of experience in healthcare and medical device technology implementation, he brings a wealth of information relating to the complexities associated with European and global clinical trial deployments.
Print this page
Send to a friend
Privacy statement
News and Press Releases

PM Group Worldwide Ltd and The Datateam Media Group announce acquisition of Samedan Ltd

PMGroup Worldwide Ltd and The Datateam Media Group are pleased and excited to announce the acquisition of pharmaceutical publishers Samedan Ltd. The deal brings together three publishing powerhouses in the pharmaceutical and healthcare sector - with Samedan joining PMGroup and PharmaTimes Media Ltd as part of The Datateam Media Group’s healthcare division.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement